In the dynamic field of myasthenia gravis (MG) treatment, characterized by recent therapeutic advancements and a promising pipeline, Nicholas J. Silvestri, MD, advises early-career professionals to approach the whole patient, considering not only the disease manifestations but also its broader impact on their lives, including work and family.
Emphasizing the importance of tailoring therapies based on individual needs, Dr Silvestri encourages early and aggressive intervention, citing evidence supporting better long-term outcomes, and underscores the significance of treating the whole patient rather than just the disease.